News Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Equities

688180

CNE1000041Z1

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
28.69 ^CNY	-5.62%		+1.02%	-31.41%

13/06	Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	MT
12/06	Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	13/06	MT
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	12/06	CI
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment	12/06	MT
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	12/06	MT
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint	12/06	GL
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	11/06	CI
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04	MT
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25/04	GL
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04	CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04	MT
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04	AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04	GL
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04	CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04	MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04	CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04	CI
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03	GL
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Equities

688180

CNE1000041Z1

Summary

Filters